Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Net Margin (2016 - 2025)

Historic Net Margin for Perspective Therapeutics (CATX) over the last 16 years, with Q2 2025 value amounting to 300.58%.

  • Perspective Therapeutics' Net Margin rose 3980000.0% to 300.58% in Q2 2025 from the same period last year, while for Sep 2025 it was 61.48%, marking a year-over-year decrease of 997600.0%. This contributed to the annual value of 67.5% for FY2024, which is 5638100.0% up from last year.
  • Latest data reveals that Perspective Therapeutics reported Net Margin of 300.58% as of Q2 2025, which was up 3980000.0% from 97.42% recorded in Q2 2024.
  • Over the past 5 years, Perspective Therapeutics' Net Margin peaked at 300.58% during Q2 2025, and registered a low of 236.92% during Q3 2022.
  • Over the past 5 years, Perspective Therapeutics' median Net Margin value was 64.01% (recorded in 2023), while the average stood at 43.51%.
  • In the last 5 years, Perspective Therapeutics' Net Margin tumbled by -1494400bps in 2022 and then soared by 3980000bps in 2025.
  • Quarter analysis of 5 years shows Perspective Therapeutics' Net Margin stood at 56.96% in 2021, then crashed by -316bps to 236.92% in 2022, then skyrocketed by 145bps to 105.73% in 2023, then tumbled by -192bps to 97.42% in 2024, then skyrocketed by 409bps to 300.58% in 2025.
  • Its last three reported values are 300.58% in Q2 2025, 97.42% for Q2 2024, and 155.07% during Q1 2024.